Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VIR Vir Biotechnology
27.070-2.380-8.08%
Close
02/08 16:00 ET
27.0700.0000.00%
Post Mkt Price 02/08 16:08 ET
High
29.050
Open
29.050
Turnover
26.08M
Low
27.040
Pre Close
29.450
Volume
940.96K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Vir Biotechnology (NASDAQ:VIR) & Brookline Capital Acquisition (NASDAQ:BCAC) Critical Analysis
Vir Biotechnology (NASDAQ:VIR – Get Rating) and Brookline Capital Acquisition (NASDAQ:BCAC – Get Rating) are both medical companies, but which is the superior business? We will contrast the two busin
A Look At The Intrinsic Value Of Vir Biotechnology, Inc. (NASDAQ:VIR)
In this article we are going to estimate the intrinsic value of Vir Biotechnology, Inc. (NASDAQ:VIR) by taking the expected future cash flows and discounting them to their present value. This will be
SVB Securities Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Endurance (Cayman) Ltd Svf Sells 78,930 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 78,930 shares of the company's stock in a transaction on Monday, January 30th. The shares were sold
GSK Q4 Sales Driven by Vaccines as Specialty Medicines See Decline; Provides FY23 Outlook
5 Value Stocks In The Healthcare Sector
Understanding Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indica
SVB Leerink Lowers Vir Biotechnology (NASDAQ:VIR) Price Target to $43.00
Vir Biotechnology (NASDAQ:VIR – Get Rating) had its price target dropped by SVB Leerink from $45.00 to $43.00 in a research note issued on Friday, Benzinga reports. The firm currently has an "outper
Morgan Stanley Upgrades Vir Biotechnology (NASDAQ:VIR) to Equal Weight
Vir Biotechnology (NASDAQ:VIR – Get Rating) was upgraded by stock analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating in a research report issued to clients and invest
Vir Upgraded at Morgan Stanley Citing Multiple Catalysts in 2023
SVB Securities Adjusts Vir Biotechnology's Price Target to $43 From $45, Maintains Outperform Rating
08:06 AM EST, 01/27/2023 (MT Newswires) -- Vir Biotechnology (VIR) has an average rating of Outperform and price targets ranging from $18 to $125, according to analysts polled by Capital IQ. Price: 30
Company Overview
More
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
CEO： Dr. George A. Scangos,PhD
Market： NASDAQ
Listing Date： 10/11/2019
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet